These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 23523308)

  • 1. MYC-y mice: from tumour initiation to therapeutic targeting of endogenous MYC.
    Morton JP; Sansom OJ
    Mol Oncol; 2013 Apr; 7(2):248-58. PubMed ID: 23523308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
    Kim J; Roh M; Abdulkadir SA
    BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
    Yu D; Thomas-Tikhonenko A
    Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of a Tetracycline Regulated Mouse Model of MYC-Induced T-Cell Acute Lymphoblastic Leukemia.
    Mahauad-Fernandez WD; Rakhra K; Felsher DW
    Methods Mol Biol; 2021; 2318():297-312. PubMed ID: 34019298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYC in oncogenesis and as a target for cancer therapies.
    Albihn A; Johnsen JI; Henriksson MA
    Adv Cancer Res; 2010; 107():163-224. PubMed ID: 20399964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways.
    Xin B; Yamamoto M; Fujii K; Ooshio T; Chen X; Okada Y; Watanabe K; Miyokawa N; Furukawa H; Nishikawa Y
    Oncogene; 2017 Sep; 36(36):5087-5097. PubMed ID: 28481866
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Tao R; Murad N; Xu Z; Zhang P; Okonechnikov K; Kool M; Rivero-Hinojosa S; Lazarski C; Zheng P; Liu Y; Eberhart CG; Rood BR; Packer R; Pei Y
    Cancer Res; 2019 Apr; 79(8):1967-1980. PubMed ID: 30862721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.
    Hoellein A; Fallahi M; Schoeffmann S; Steidle S; Schaub FX; Rudelius M; Laitinen I; Nilsson L; Goga A; Peschel C; Nilsson JA; Cleveland JL; Keller U
    Blood; 2014 Sep; 124(13):2081-90. PubMed ID: 25143484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concepts to Target MYC in Pancreatic Cancer.
    Wirth M; Mahboobi S; Krämer OH; Schneider G
    Mol Cancer Ther; 2016 Aug; 15(8):1792-8. PubMed ID: 27406986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases.
    Sipos F; Firneisz G; Műzes G
    World J Gastroenterol; 2016 Sep; 22(35):7938-50. PubMed ID: 27672289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal cooperation between mutant Hras and c-myc or TGFα in the regulation of mouse hepatocyte growth or transformation in vivo.
    Stein TJ; Bowden M; Sandgren EP
    Liver Int; 2011 Oct; 31(9):1298-305. PubMed ID: 22093452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taking on challenging targets: making MYC druggable.
    Horiuchi D; Anderton B; Goga A
    Am Soc Clin Oncol Educ Book; 2014; ():e497-502. PubMed ID: 24857145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long journey to bring a Myc inhibitor to the clinic.
    Whitfield JR; Soucek L
    J Cell Biol; 2021 Aug; 220(8):. PubMed ID: 34160558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A big step for MYC-targeted therapies.
    Atibalentja DF; Deutzmann A; Felsher DW
    Trends Cancer; 2024 May; 10(5):383-385. PubMed ID: 38580534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: implications for anticancer therapy.
    Lin CJ; Malina A; Pelletier J
    Cancer Res; 2009 Oct; 69(19):7491-4. PubMed ID: 19773439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation of p53 serine 18 upregulates apoptosis to suppress Myc-induced tumorigenesis.
    Sluss HK; Gannon H; Coles AH; Shen Q; Eischen CM; Jones SN
    Mol Cancer Res; 2010 Feb; 8(2):216-22. PubMed ID: 20145032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics.
    Chen BJ; Wu YL; Tanaka Y; Zhang W
    Int J Biol Sci; 2014; 10(10):1084-96. PubMed ID: 25332683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
    Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
    Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The many faces of c-MYC.
    Pelengaris S; Khan M
    Arch Biochem Biophys; 2003 Aug; 416(2):129-36. PubMed ID: 12893289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Driver or passenger effects of augmented c-Myc and Cdc20 in gliomagenesis.
    Ji P; Zhou X; Liu Q; Fuller GN; Phillips LM; Zhang W
    Oncotarget; 2016 Apr; 7(17):23521-9. PubMed ID: 26993778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.